ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have earned an average rating of "Buy" from the six research firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $8.83.

PRQR has been the subject of a number of research analyst reports. StockNews.com lowered ProQR Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, November 28th. JMP Securities reiterated a "market outperform" rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target for the company. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, Chardan Capital reiterated a "buy" rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th.

Remove Ads

ProQR Therapeutics Trading Down 0.4 %

NASDAQ PRQR traded down $0.01 on Tuesday, hitting $2.33. 327,464 shares of the company were exchanged, compared to its average volume of 307,543. The company has a market cap of $190.31 million, a PE ratio of -7.28 and a beta of 0.26. The stock has a fifty day moving average of $2.41 and a 200-day moving average of $2.63. ProQR Therapeutics has a 12 month low of $1.61 and a 12 month high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds have recently modified their holdings of PRQR. Privium Fund Management B.V. increased its position in shares of ProQR Therapeutics by 0.9% during the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock valued at $10,251,000 after acquiring an additional 51,663 shares during the last quarter. OneDigital Investment Advisors LLC grew its stake in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 15,550 shares during the period. BNP Paribas Financial Markets increased its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 7,300 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth $61,000. Finally, M&T Bank Corp bought a new stake in shares of ProQR Therapeutics during the 4th quarter worth $330,000. Institutional investors own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).